PharmaVOICE - 
January 2009
Purchase Issue

In Every Issue
Last Word
Sirtris’ Dr. Michelle Dipp discusses maintaining corporate culture while integrating [...]
By
Talent Pool
Pharmaceutical POOL Alex Gorsky Sheri McCoy Johnson & Johnson Shifts [...]
By
On The Calendar
January 15-16 Next Generation Clinical Research Associates Loews Philadelphia Hotel, [...]
By
E-Media
Integromics and Tibco Spotfire Launch Genomics Data Analysis Tool GEL [...]
By
What’s New
Parexel Offers early-Study Support Parexel International is providing companies with [...]
By
PharmaTrax
Cost Deters Cancer Patients from Seeking Treatment In addition to [...]
By
PharmaOutlet
Contributed by Terry Nugent No doubt change is in the [...]
By

Terry Nugent

UpFront
Milestones WOTY Award Turns 20 In 2009, the Healthcare Businesswomen’s [...]
By
Letter from the Editor
Business not as usual. This month’s Forum — Virtual Pharma: [...]
By

Taren Grom, Editor

On The Cover

Partnering for Success
Mitigate risk by reading red flags Creating effective partnerships is more crucial than ever, so being able to spot red flags from a distance, and knowing how to deal with potential problems close up is of great value today. Careful planning, goal setting, and communication can improve the success rate of any union. Atkins. Endo. [...]
By

Robin Robinson

Features

IRBs: Training for Patient Protection
IRB’s Training for Subject Protection In the absence of a regulation requiring training and education for those involved with clinical study subjects, many IRBs and investigator sites are voluntarily putting their staffs through the paces to ensure patients are protected. BY DENISE MYSHKO Protecting patients’ rights during the clinical study process is paramount to ensuring [...]
By

Denise Myshko

Reaching The Higher Ground Through Higher Education
With the economy in turmoil and job cuts at the highest level since 2002, the pharmaceutical industry is under extreme pressures — layoffs, increased regulatory scrutiny, generic competition, pricing constraints, escalating R&D costs, etc. To thrive, no less survive, in these trying times, companies need leadership from their best and brightest employees to find solutions [...]
By

Denise Myshko

John Crowley — Journey of the Heart
When presented with shocking news concerning the health of his two youngest children, John Crowley responded by embarking on a mission to help uncover a novel therapeutic option for treating Pompe disease, a lysosomal storage disease (LSD) that, like other LSDs, interferes with the body’s ability to break down molecules inside the lysosomes, compartments inside [...]
By

Kim Ribbink

The Benefits of Prelaunch Access
Contributed by Natalie Douglas, CEO, IDIS Prelaunch access to drugs can provide months and perhaps years of treatment for patients with unmet medical needs when all other therapeutic options have failed or no other options are available. The benefits of named- patient programs are best realized when a company incorporates planning for such programs early [...]
By

Natalie Douglas, CEO, IDIS

The Green of Going Green
The pharmaceutical industry has made enormous strides to limit its impact on the environment and create projects that improve sustainability. Increasingly, this socially responsible approach also makes good business sense, as more companies are discovering. Doing good and doing well may well be synonymous. Pharmaceutical companies have been making significant strides toward environmental sustainability, putting [...]
By
No Pens or Mugs? No Problem.
The industry is discovering it won’t lose its ability to message effectively under the new PhRMA code. Under the new PhRMA code, the exhibit hall of the future will contain no tchotchkes. Sales reps will no longer stop by the physician’s office with donuts, pens, and sticky notes. The question is: how in the world [...]
By

Robin Robinson

FEEDBACK